📰 Dystrophy Type News
Dystrophy Type News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dystrophy Type. Real-time updates on events, politics, business and more.
May 20, 2024
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia,...
May 20, 2024
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - ...
January 7, 2024
BOSTON, January 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 a.m. ET/8:15 a.m. PT.
May 25, 2023
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), a clinical-stage pharmaceutical company, Thursday, announced that its investigational drug DYNE-101 has been granted orphan drug
February 22, 2023
Living organisms have a knack for persisting in the face of challenges. For instance, when genes malfunction, organisms may be able to compensate by activating redundant genes with similar functions, called paralogs.
February 21, 2023
Living organisms have a knack for persisting in the face of challenges
February 11, 2022
Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to...
December 23, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.